This website uses cookies to improve your online experience. They are placed on your computer when you launched this website. You can change your cookie settings through your browser. If you continue to use this site, you consent to our use of cookies. Cookies Policy.

Contact Us

Corporate News

2025

01 December
XENOVIEW® 3T coil passes Philips compatibility testing
25 November
First Polarean Xenon Hyperpolariser to be installed in Asia
24 November
Korean distributor agreement with DK Healthcare in South Korea
14 November
Proposed Cancellation of Admission & Notice of GM
27 October
Holding(s) in Company
22 October
Strategic Review and Consideration of AIM Listing Status
06 October
Ascend Imaging agreement expansion
29 September
University of Virginia Health Hospital new supply agreement
25 September
National Institutes of Health orders Polarean's HPX Hyperpolarisation system
25 September
Half-year Report
16 September
Notice of results
11 September
Holding(s) in Company
12 August
Submission of new Phase III study protocol to FDA for expanded indication of XENOVIEW
24 July
Block Listing Six Monthly Return
24 June
Promotion & Sales Representative Agreement
09 June
Result of AGM
02 June
FDA expands XENOVIEW® indication to include children from six years of age
21 May
American Thoracic Society honours Dr. Bastiaan Driehuys for pioneering work in Xenon MRI
15 May
Xenon MRI featured prominently at ATS 2025
14 May
Ongoing collaboration with Philips
08 May
Final Results
06 May
Holding(s) in Company
25 April
Notice of results
10 March
Expansion of Xenon MRI imaging platform for pharma-sponsored research
27 February
FY24 Trading Update
19 February
Virtual Investor Day
03 February
Taiwanese distributor agreement with Sumtage
30 January
Key Patent in China Secured
28 January
Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation
24 January
Block Listing Six Monthly Return

2024

11 December
Holding(s) in Company
21 November
FDA clears XENOVIEW® 3T Chest Coil in GE HealthCare MRI Systems
25 September
Virtual Investor Day
04 September
Half-year Report
03 September
Appointment of Alan Huang, Ph.D., as Vice President of Sales
28 August
Appointment of Chase Hall, M.D., as Chief Medical Advisor
21 August
Notice of results
15 August
Appointment of Bastiaan Driehuys as consultant
01 August
FDA submission to expand minimum age for XENOVIEW™
31 July
New Xenon MRI System trade-in agreement entered with the University of Kansas Medical Center
29 July
Repricing of Options and Grant of Options
26 July
Block Listing Six Monthly Return
24 July
Result of AGM
19 July
Xenon MRI System trade-in agreement entered with the University of Virginia Health Hospital
18 July
PDMR Dealing
28 June
Final Results and Directorate Changes
19 June
Holding(s) in Company
19 June
Holding(s) in Company
19 June
Holding(s) in Company
19 June
Holding(s) in Company
19 June
Holding(s) in Company
19 June
Holding(s) in Company
18 June
Holding(s) in Company
18 June
Holding(s) in Company
14 June
Result of General Meeting, Open Offer Update and Total Voting Rights
23 May
Posting of Circular
22 May
Result of Placing and Subscription, PDMR Dealings
21 May
Proposed Placing, Subscription and Open Offer
10 May
New Xenon MRI System order received
08 May
Xenon MRI to be featured at ATS 2024 conference
03 May
Order received for upgraded hyperpolariser
16 April
U.S. Patent granted for dynamic cardiopulmonary blood flow imaging with Xenon MRI
14 March
Exercise of Warrants, PDMR Dealing, Issue of Equity and Total Voting Rights
12 March
Holding(s) in Company
29 February
2024 Polarean Strategy Update
26 January
Block Listing Six Monthly Return
15 January
Comment re: share purchase
12 January
Holding(s) in Company
12 January
Holding(s) in Company

2023

07 December
Company Update
27 November
Holding(s) in Company
27 September
Directorate appointment
08 September
Partnership with VIDA to streamline adoption of advanced MRI of the lungs
07 September
Half-year Report - Amendment
07 September
Half-year Report
05 September
Reimbursement code price range for XENOVIEW
29 August
CMS grants reimbursement code for the Polarean XENOVIEW™ MRI Technology
21 August
Holding(s) in Company
15 August
Notice of results
09 August
Holding(s) in Company
07 August
Exercise of Warrants, PDMR Dealing, Issue of Equity and Total Voting Rights
03 August
Polarean Receives Clearance for New MRI Chest Coil
31 July
University of Missouri Health Care to begin clinical imaging with XENOVIEWTM Conversion
27 July
Block Listing Six Monthly Return
30 June
Exercise of Warrants, PDMR Dealing, Issue of Equity and Total Voting Rights
28 June
Result of AGM
21 June
Appointment of Dr. Christopher von Jako as new CEO
02 June
Collaboration with Philips to be featured at ISMRM 2023
02 June
Extension of Warrants
26 May
Final results for the year ended 31 December 2022
11 May
First clinical scan using XENOVIEWTM in Cincinnati
03 May
Featured at 2023 ATS Respiratory Innovation Summit
26 April
First order for XENOVIEWTM gas blend received from Cincinnati Children’s Hospital Medical Center
17 April
Appointment of Dan Brague as consultant
14 March
RESTORATION OF TRADING ON AIM
14 March
Request for temporary suspension from trading on AIM to be lifted
13 March
TEMPORARY SUSPENSION OF TRADING ON AIM
13 March
Silicon Valley Bank Relationship, Request for temporary suspension from trading on AIM
15 February
Investor presentation
13 February
Company Update
01 February
FDA grants New Chemical Entity designation for XENOVIEW
27 January
Block Listing Six Monthly Return

2022

28 December
FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized)
30 September
Update on New Drug Application
22 September
Update on New Drug Application
31 August
Half-year Report
26 August
Director appointment
28 July
Total voting rights and Block Listing Return
08 July
System delivery
29 June
Result of AGM
18 May
Final Results for the Year Ended 31 December 2021
11 May
Notice of Results
11 May
Research collaboration with Oxford University Hospitals for long COVID
05 May
Directorate changes
29 April
Total voting rights
25 April
New system order
20 April
New Drug Application Resubmission update
14 April
Appointment of Non-Executive Director
08 April
Exercise of Options, PDMR Dealing, Issue of Equity and Total Voting Rights
31 March
New Drug Application Resubmission
25 February
Total voting rights
14 February
New system order
28 January
Block Listing Return
28 January
Total Voting Rights
04 January
Total Voting Rights

2021

30 November
Total Voting Rights
11 October
System Installation
11 October
Director dealing
06 October
Complete Response Letter received from FDA
24 September
Transfer of warrants
03 September
Holding(s) in Company
02 September
Half-year Report
31 August
Total Voting Rights
23 July
Block listing application
13 July
Result of AGM
09 July
Grant of Options and Director Compensation Reduction
07 July
New System Installation
04 June
Final Results for the Year Ended 31 December 2020
26 May
Article on hyperpolarised xenon
25 May
Conference attendance at Mello
17 May
Exercise of Warrants
14 May
Conference attendances
10 May
New System Order
16 April
Exercise of Warrants
06 April
Result of General Meeting, Open Offer Update and Total Voting Rights
06 April
Result of Open Offer
01 April
Total Voting Rights
29 March
Investor presentation
25 March
Exercise of Warrants
16 March
Publication of Circular and Notice of General Meeting
16 March
Result of Placing and Subscription, PDMR Dealings and Notice of General Meeting
15 March
Proposed Placing, Subscription and Open Offer
24 February
Exercise of Warrants
22 February
Board appointment
25 January
Change of Nominated Adviser

2020

23 December
FDA acceptance for the filing of New Drug Application
04 December
Appointment of Joint Corporate Broker
30 October
Total Voting Rights
20 October
Exercise of Warrants
12 October
New System Order
08 October
Holding(s) in Company
07 October
NDA Submission
30 September
Half-year Report
18 September
New System Installation
30 July
Scientific presentations on hyperpolarized Xenon
13 July
Result of AGM
18 June
Final Results
01 June
Exercise of Warrants
01 June
Appointment of Non-Executive Director
30 April
Total Voting Rights
02 April
Holding(s) in Company
02 April
Holding(s) in Company
01 April
Result of General Meeting & Completion of Fundraise
31 March
Total Voting Rights
25 March
General Meeting: Change of Venue
13 March
Conditional Fundraise to raise £8.4 million, Notice of General Meeting
02 March
Exercise of Warrants
03 February
Directorate Change
29 January
Positive results from pivotal Phase III Clinical Trials
22 January
Director Dealing
13 January
Holding(s) in Company
02 January
Director Dealing

2019

24 December
New System Delivery and Installation
12 November
New System Delivery and Installation
08 November
Grant of Options
07 November
Completion of patient enrolment for Clinical Trials and PDMR Appointment
11 October
Director Dealing
11 October
Polarean notes statement from Amphion Innovations
09 October
Holding(s) in Company
03 October
Polarean notes statement from Amphion Innovations
25 September
Polarean notes statement from Amphion Innovations
24 September
Half-year Report
10 September
Polarean notes statement from Amphion Innovations
10 September
New System Installation
09 August
Polarean notes statement from Amphion Innovations
05 August
Phase III Clinical Trials update First patient enrolment at University of Cincinnati
31 July
Total Voting Rights
30 July
Holding(s) in Company
30 July
Holding(s) in Company
29 July
Holding(s) in Company
25 July
Result of AGM
24 July
Exercise of Warrants
22 July
Placing to raise £2.1 million
11 July
New System Order
27 June
Final Results
13 June
Investor Symposium presentations available online
11 June
Phase III Clinical Trials - Update
05 June
New System Order
23 May
Grant of Share Options
23 May
London Investor Symposium Wednesday 12 June 2019
21 May
Third tranche of $3m paediatric lung disease imaging study grant confirmed
13 May
Phase III Clinical Trial Update
30 April
Total Voting Rights
29 April
Appointment of Chief Financial Officer
02 April
Exercise of Warrants
01 April
Amphion Innovations plc - Pledge of Polarean shares
15 February
New System Order with the University of British Columbia
24 January
Appointment of Nominated Adviser and Broker
21 January
Holding(s) in Company
03 January
Holding(s) in Company

2018

28 December
Result of General Meeting and Total Voting Rights
11 December
Conditional Fundraise to raise US$4 million
13 November
Licencing Agreement with Duke University
06 November
Company Update
05 November
Nominated Adviser Status
03 October
Delivery of Xenon Polariser
23 August
First patient IN Phase III FDA clinical trial
22 August
Half-year Report
27 July
Company Update
18 July
Result of AGM
17 July
Holding(s) in Company
10 July
Result of Placing
09 July
Proposed Placing to raise a minimum of £0.78 million
21 June
Holding(s) in Company
19 June
Investor Symposium
13 June
Final Results
06 June
Delivery of Xenon Polariser
31 May
London Investor Symposium Tuesday 19 June 2018
22 May
Delivery of Xenon Polariser
20 April
Grant of Share Options
17 April
Polarean technology used in severe asthma study
29 March
Admission to trading on AIM and First Day of Dealings
26 March
US based medtech company seeks AIM IPO

Latest News

About Us

Share Price

-
GBp
-
-
-

Latest Annual Report

 


 

Important dates

15 Dec
General Meeting
25 Sep
Half-year Report

Investor Alert

Sign up for Email Alerts